Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target

Figure 1

UBE2C was differentially expressed in many cancer types. (a) UBE2C overall survival analysis in 33 cancer types. The high UBE2C expression level was related to poor prognosis. (b) Differentially expressed analysis in 33 cancer types. UBE2C was differentially expressed in 24 cancer types. Owing to no normal controls, differential expression was not performed in 9 cancer types including ACC, DLBC, LAML, LGG, MESO, OV, TGCT, UCS, and UVM. , , and .

(a)

(b)